Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.79 |
| ▸ | CES1 | P23141 | 3/20 | 0.77 |
| ▸ | CES2 | O00748 | 1/20 | 0.77 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.77 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.77 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.77 |
| ▸ | POLB | P06746 | 3/20 | 0.76 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.76 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.76 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.76 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.76 |
| ▸ | PTPRC | P08575 | 2/20 | 0.76 |
| ▸ | PTPRF | P10586 | 2/20 | 0.76 |
| ▸ | F3 | P13726 | 2/20 | 0.76 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.76 |
| ▸ | ACP1 | P24666 | 2/20 | 0.76 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.76 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.76 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beta-Amyrin SCHEMBL17124229 | 1.00 | USP2 (1.00) | USP2ALOX5CES1CES2PTPN1 | |
| Beta-Amyrin SCHEMBL1696465 | 1.00 | USP2 (1.00) | USP2ALOX5CES1CES2PTPN1 | |
| Beta-Amyrin SCHEMBL12313094 | 1.00 | USP2 (1.00) | USP2ALOX5CES1CES2PTPN1 | |
| Beta-Amyrin SCHEMBL18687837 | 1.00 | USP2 (1.00) | USP2ALOX5CES1CES2PTPN1 | |
| Beta-Amyrin SCHEMBL377754 | 1.00 | USP2 (1.00) | USP2ALOX5CES1CES2PTPN1 | |
| Beta-Amyrin SCHEMBL1696463 | 1.00 | USP2 (1.00) | USP2ALOX5CES1CES2PTPN1 | |
| Beta-Amyrin SCHEMBL3119711 | 1.00 | USP2 (1.00) | USP2ALOX5CES1CES2PTPN1 | |
| Beta-Amyrin SCHEMBL18376076 | 1.00 | USP2 (1.00) | USP2ALOX5CES1CES2PTPN1 | |
| Beta-Amyrin SCHEMBL14226156 | 1.00 | USP2 (1.00) | USP2ALOX5CES1CES2PTPN1 | |
| Beta-Amyrin SCHEMBL2025280 | 1.00 | USP2 (1.00) | USP2ALOX5CES1CES2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113013-A1 | SYNERGISTIC COMPOSITIONS FOR IMPROVING BRAIN HEALTH | LAILA NUTRA PRIVATE LIMITED (IN) | 2023-04-13 | — | — | US | disclosed |
| WO-2021176469-A1 | SYNERGISTIC COMPOSITIONS FOR IMPROVING BRAIN HEALTH | LAILA NUTRACEUTICALS (IN) | 2021-09-10 | — | — | WO | disclosed |
| US-9101599-B2 | Synergistic anti-inflammatory compositions comprising Boswellia serrata extracts | LAILA NUTRACEUTICALS (US) | 2015-08-11 | — | — | US | disclosed |
| US-8551496-B2 | Boswellia low polar gum resin extract and its synergistic compositions | LAILA NUTRACEUTICALS (IN) | 2013-10-08 | — | — | US | disclosed |
| US-20130084348-A1 | COMPOSITIONS COMPRISING NON-ACIDIC BOSWELLIA OIL FRACTION AS A BIO-ENHANCER FOR ENHANCING BIOAVAILABILITY OF BIOLOGICAL AGENTS | LAILA NUTRACEUTICALS (IN) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113013-A1 | SYNERGISTIC COMPOSITIONS FOR IMPROVING BRAIN HEALTH | FABP7, FOSB, BCHE | USP2 741/4885ALOX5 308/4885CES1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.